Reversible cerebral vasoconstriction syndrome and posterior reversible encephalopathy syndrome following vaccination: analysis of the VAERS database and systematic review

被引:1
|
作者
Srichawla, Bahadar S. [1 ,3 ]
Fang, Ton [1 ]
Kipkorir, Vincent [2 ]
Garcia-Dominguez, Maria A. [1 ]
机构
[1] Univ Massachusetts, Chan Med Sch, Dept Neurol, Worcester, MA USA
[2] Univ Nairobi, Dept Med, Nairobi, Kenya
[3] 55 Lake Ave N, Worcester, MA 01655 USA
来源
ANNALS OF MEDICINE AND SURGERY | 2024年 / 86卷 / 03期
关键词
posterior reversible encephalopathy syndrome; PRES; RCVS; reversible cerebral vasoconstriction syndrome; vaccination; vaccine;
D O I
10.1097/MS9.0000000000001407
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives:This study aimed to analyze the Vaccine Adverse Event Reporting System (VAERS) database and systematically review the literature to provide a comprehensive analysis of reversible cerebral vasoconstriction syndrome (RCVS) and posterior reversible encephalopathy syndrome (PRES) secondary to vaccination.Methods:The authors analyzed the VAERS database and conducted a systematic review following PRISMA guidelines. The inclusion criteria for VAERS data were a score of >= 3 on the RCVS2 score and/or radiographic findings consistent with the diagnosis of RCVS or PRES. The systematic review was registered with PROSPERO.Results:Our combined data set included 29 cases (9 RCVS and 20 PRES). Most cases were women (72.4%) with a mean age of 50.7 years (SD 19.4 years). Most cases were associated with COVID-19 mRNA vaccines (58.6% Moderna, 20.7% Pfizer). Hypertension (37.9%), hyperlipidemia (13.7%), chronic kidney disease (CKD) (10.3%), and end-stage renal disease (6.8%) were common comorbidities. Furthermore, 20.6% (6/29) of cases were on immunosuppression therapy for various reasons. The mean time to symptom onset was 10.49 days after vaccination (SD 18.60), and the mean duration of hospitalization was 7.42 days (SD 5.94). The symptoms reported the most frequently were headache (41.3%), elevated blood pressure (31.0%), and emesis (17.2%). Typical radiographic findings included T2/FLAIR hyperintensities affecting the parieto-occipital lobes, indicative of vasogenic and/or cytotoxic edema.Conclusions:This study provides a comprehensive analysis of postvaccine RCVS and PRES. Both disease states were seen most often in those with pre-existing risk factors such as female sex, age over 50, hypertension, renal disease, and immunosuppression. Vaccines and their associated immune response may cause endothelial dysfunction leading to cerebral vasospasm and loss of cerebral autoregulation. However, further research is required to understand the underlying pathophysiological mechanisms. Despite the associations found, the absolute risk of these syndromes remains extremely low compared to the immense benefits of vaccination.
引用
收藏
页码:1251 / 1260
页数:10
相关论文
共 50 条
  • [21] Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome in patients with COVID-19 infection: is there a link? A systematic review and case report analysis
    Bonura, Adriano
    Iaccarino, Gianmarco
    Rossi, Sergio Soeren
    Capone, Fioravante
    Motolese, Francesco
    Calandrelli, Rosalinda
    Di Lazzaro, Vincenzo
    Pilato, Fabio
    JOURNAL OF NEUROLOGY, 2023, 270 (06) : 2826 - 2852
  • [22] Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome in patients with COVID-19 infection: is there a link? A systematic review and case report analysis
    Adriano Bonura
    Gianmarco Iaccarino
    Sergio Soeren Rossi
    Fioravante Capone
    Francesco Motolese
    Rosalinda Calandrelli
    Vincenzo Di Lazzaro
    Fabio Pilato
    Journal of Neurology, 2023, 270 : 2826 - 2852
  • [23] Systematic review of reversible cerebral vasoconstriction syndrome
    Sattar, Ahsan
    Manousakis, Georgios
    Jensen, Matthew B.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2010, 8 (10) : 1417 - 1421
  • [24] Posterior reversible encephalopathy syndrome following measles vaccination
    Hamano, Tadanori
    Takeda, Tomoko
    Morita, Hiroshi
    Muramatsu, Tomoko
    Yoneda, Makoto
    Kimura, Hirohiko
    Kuriyama, Masaru
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2010, 298 (1-2) : 124 - 126
  • [25] Pediatric Reversible Cerebral Vasoconstriction Syndrome/Posterior Encephalopathy Syndrome/Poststreptococcal Glomerulonephritis
    Kawashima, Yuki
    Ariji, Shohei
    Aoyagi, Rui
    Noda, Masahiro
    Oba, Kunihiro
    Ogasawara, Masashi
    PEDIATRIC NEUROLOGY, 2024, 155 : 33 - 35
  • [27] Frequency of ischaemic stroke and intracranial haemorrhage in patients with reversible cerebral vasoconstriction syndrome (RCVS) and posterior reversible encephalopathy syndrome (PRES) - A systematic review
    Kaufmann, Jana
    Buecke, Philipp
    Meinel, Thomas
    Beyeler, Morin
    Scutelnic, Adrian
    Kaesmacher, Johannes
    Mujanovic, Adnan
    Dobrocky, Thomas
    Arsany, Hakim
    Peters, Nils
    Z'Graggen, Werner
    Jung, Simon
    Seiffge, David
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (05)
  • [28] Reversible Cerebral Vasoconstriction Syndrome (RCVS) After COVID-19 Vaccination: An Analysis of VAERS
    Srichawla, Bahadar
    NEUROLOGY, 2023, 100 (17)
  • [29] Assessment of Noninvasive Regional Brain Oximetry in Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome
    Chung, David Y.
    Claassen, Jan
    Agarwal, Sachin
    Schmidt, J. Michael
    Mayer, Stephan A.
    JOURNAL OF INTENSIVE CARE MEDICINE, 2016, 31 (06) : 415 - 419
  • [30] A Comparison of Clinical Features Between Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral Vasoconstriction Syndrome.
    Toljan, Karlo
    Scarsella, Monica
    Purohit, Meghan
    Wisco, Dolora R.
    Uchino, Ken
    STROKE, 2021, 52